KCNK3 and pulmonary arterial hypertension: In the work identifying KCNK3 mutations in PAH, Ma and colleagues demonstrated that ONO-RS-082 is able to re-activate some KCNK3 mutants, suggesting that this molecule could be a beneficial therapeutic approach to target KCNK3 in PAH [11].